RCC2: A Potential Drug Target for Urological Malignancies (G55920)

Target Name: RCC2

NCBI ID: G55920

RCC2

RCC2: A Potential Drug Target for Urological Malignancies

RCC2 (Renal-critical care unit 2) is a unit of the German Cancer Research Center (DKFZ) in Heidelberg, Germany. RCC2 is responsible for providing intensive care for patients with urological malignancies, including kidney cancer. The success of renal cancer treatment is heavily dependent on early detection and aggressive therapy. Therefore, the identification of potential drug targets and biomarkers is of great interest for the development of new treatment strategies.

Target Identification

RCC2 has been identified as a potential drug target due to its involvement in several key cellular processes that are critical for cancer growth and progression. RCC2 has been shown to play a role in the development and maintenance of cancer stem cells, which are a major concern in urological malignancies.

Additionally, RCC2 has been associated with the development of resistance to chemotherapy in urological malignancies. Chemotherapy is a common treatment for cancer, but resistance to chemotherapy drugs is a serious problem. Therefore, studying the role of RCC2 in chemotherapy resistance can provide new treatment strategies.

Expression of RCC2

RCC2 has been shown to be highly expressed in various urological malignancies, including kidney cancer. It is a protein that is expressed in the renal cortical collecting tubules, which are the specialized structures responsible for collecting urine from the kidneys. RCC2 is involved in the regulation of the cytoskeleton and cell adhesion, which are critical for the maintenance of cancer stem cells.

The cytoskeleton is the framework that organizes the cell's structure and functions. It is responsible for the regulation of cell division, the assembly and disassembly of organelles, and the movement of cells. The cytoskeleton is also involved in the regulation of cell-cell and cell -tissue interactions, which are critical for the maintenance of stem cells.

In addition, RCC2 is involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. Adhesion is a critical process for the development and maintenance of tissues and organs, and it is also involved in the regulation of stem cell maintenance.

Drug Targeting

RCC2 has been shown to be a potential drug target in urological malignancies. Studies have shown that inhibiting RCC2 can lead to the inhibition of the growth and survival of cancer stem cells. Additionally, inhibiting RCC2 has been shown to improve the efficacy of chemotherapy in urological malignancies.

One of the most promising compounds that has been shown to inhibit RCC2 is 2-methylpropionitrile (2-MP), which is a small molecule inhibitor of RCC2. 2-MP has been shown to inhibit the growth of urological cancer stem cells in cell culture and animal models.

Another promising compound that has been shown to inhibit RCC2 is quercetin, which is a flavonoid found in various fruits and vegetables. Quercetin has been shown to inhibit the growth of urological cancer stem cells in cell culture and animal models.

Conclusion

RCC2 is a protein that has been shown to play a critical role in the development and maintenance of urological malignancies. The identification of potential drug targets and biomarkers, such as 2-MP and quercetin, has the potential to lead to new treatment strategies for urological malignancies. Further research is needed to confirm the effectiveness of these compounds and to develop new strategies for the treatment of urological malignancies.

Protein Name: Regulator Of Chromosome Condensation 2

Functions: Multifunctional protein that may affect its functions by regulating the activity of small GTPases, such as RAC1 and RALA (PubMed:12919680, PubMed:25074804, PubMed:26158537, PubMed:28869598). Required for normal progress through the cell cycle, both during interphase and during mitosis (PubMed:23388455, PubMed:12919680, PubMed:26158537). Required for the presence of normal levels of MAD2L1, AURKB and BIRC5 on inner centromeres during mitosis, and for normal attachment of kinetochores to mitotic spindles (PubMed:12919680, PubMed:26158537). Required for normal organization of the microtubule cytoskeleton in interphase cells (PubMed:23388455). Functions as guanine nucleotide exchange factor (GEF) for RALA (PubMed:26158537). Interferes with the activation of RAC1 by guanine nucleotide exchange factors (PubMed:25074804). Prevents accumulation of active, GTP-bound RAC1, and suppresses RAC1-mediated reorganization of the actin cytoskeleton and formation of membrane protrusions (PubMed:25074804, PubMed:28869598). Required for normal cellular responses to contacts with the extracellular matrix of adjacent cells, and for directional cell migration in response to a fibronectin gradient (in vitro) (PubMed:25074804, PubMed:28869598)

The "RCC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RCC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets